Navigation Links
Bayer HealthCare and Juvaris BioTherapeutics Announce Major Licensing Agreement
Date:3/4/2008

In commenting on behalf of Juvaris, Martin D. Cleary, Co-Founder and Chairman of the Board of Juvaris, said, "We are delighted to put this agreement in place with an established veterinary franchise such as Bayer Animal Health. The world's animal health marketplace is basically underserved and to have a company willing to develop products, for which there are currently no approved human counterparts, is truly unusual in this space. We look forward to a long and productive relationship with Bayer Animal Health."

Kimberlee Gonzaga, Chief Financial Officer of Juvaris said, "Although human health is our intended market, this relationship offers Juvaris an opportunity to generate non-dilutive cash flows that will be used to support this deal, to further develop our product portfolio and most importantly to support human clinical trials. Our organization has an opportunity to genuinely impact the prevention and treatment of infectious diseases and cancer. This helps Juvaris to advance to the next step in this effort."

The companies have created a joint steering committee made up of Bayer Animal Health and Juvaris BioTherapeutics executives to ensure the required tasks are properly understood and executed.

About Juvaris BioTherapeutics

Juvaris BioTherapeutics was created in 2003 to develop an immunotherapeutic product platform for the treatment of infectious diseases and cancers using lipid-DNA complexes. Cationic lipids are formulated with non-coding DNA (plasmid) to create the JuvImmune (JVRS-100) Immunostimulant, a lipid-DNA complex, which as a single product will have utility in multiple infectious disease and cancer applications. The JuvImmune product has been shown to be at least 50-times more potent at triggering innate immune activation and interferon release than current immune stimulants.

When combined with disease-specific antigens, the technology creates JuvaVax vaccines capable of activating substantial antibody- and
'/>"/>

SOURCE Juvaris BioTherapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. 60 Minutes to Report on Dangers of Trasylol: Cory Watson Crowder & DeGaris Involved in Litigation Against Pharmaceutical Giant Bayer AG
2. Bayer Establishes US Special Access Program for Leukine(R) While Replacing Current Liquid Formulation
3. Bayer Corporation Renames Its U.S. Foundation, Refocuses Charitable Giving Areas
4. New Bayer, United Nations Partnership Brings International Environment and Art Competition to Local Elementary and Middle Schools
5. New Bayer, United Nations Partnership Brings International Environment and Art Competition to Pittsburgh-Area Elementary and Middle Schools
6. New Bayer, United Nations Partnership Brings International Environment and Art Competition to Northern New Jersey Elementary and Middle Schools
7. New Bayer, United Nations Partnership Brings International Environment and Art Competition to Kansas City Area Elementary and Middle Schools
8. AUDIO from Medialink and Bayer: Use Caution When Choosing Your Cold Medicine
9. Bayer CropScience, Mertec and M.S. Technologies to Co-Develop New Soybean Trait Products
10. Bayer HealthCare Pharmaceuticals and MedAssets Supply Chain Systems Sign a Three-Year Agreement for Magnevist(R) Magnetic Resonance Contrast Media
11. Bayer Awards Making Science Make Sense Grant to Girl Scouts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/15/2008)...t safety in hospitals focus of 48 NQF-endorsed mea... -- Recognizing that patient,safety remains a majo...y,Forum (NQF) today endorsed 48 voluntary consensu...f acute care hospitals, including measures,address...evention and care,of venous thromboembolism., "It...
(Date:5/15/2008)...es not appear to help quality of life for lung can...ay 15 (HealthDay News) -- Adding chemotherapy to o...thelioma, a lung cancer usually linked to asbestos...val or quality of life. , Malignant pleural mes...er of the protective lining that covers the lungs....
(Date:5/15/2008)...ommends Governor Paterson,s leadership in proposin...ncy, ALBANY, N.Y., May 15 /PRNewswire-USNewswire/...t interest in passing the Governor,s prescription,... influence that,pharmaceutical companies have over...ers, pocket books but the treatment they receive.,...
(Date:5/15/2008)...D, Calif., May 15 /PRNewswire-FirstCall/ -- (Nasda...ompany") today announced that, on May,12, 2008, it...stating that,the Company,s requests for continued ...ed. The NASDAQ noted that the Company did not prov...hieve near term compliance with,the continued list...
Breaking Medicine News(10 mins):Health News:National Quality Forum Endorses Consensus Standards for Quality of Hospital Care 2Health News:National Quality Forum Endorses Consensus Standards for Quality of Hospital Care 3Health News:National Quality Forum Endorses Consensus Standards for Quality of Hospital Care 4Health News:National Quality Forum Endorses Consensus Standards for Quality of Hospital Care 5Health News:Chemo for Mesothelioma Offers Limited Survival Benefits 2Health News:AARP Statement on Governor's Bill for Prescription Drug Marketing Reform and Transparency 2Health News:WorldHeart Announces Possible Delisting Action by NASDAQ 2Health News:WorldHeart Announces Possible Delisting Action by NASDAQ 3
...ey transplant in Canada can differ according to pr...e Canadian Medical Association Journal.// People ... to receive a replacement kidney than those in Ont...year period found. Saskatchewan, Atlantic Canada's...
...hours a person works, the greater his chances for ...PhD; Dean Baker, MD, MPH; and colleagues at the// ...n 24,000 people in a telephone survey conducted in...o worked 40 hours a week are 14 percent more likel...
...nal AIDS Conference was held recently in Toronto. ... the world had participated.// The conference emph...n the programs launched not only in within their t.... Around 5 years back, many experts thought that i...
... Stanford University has shown that the fog of alc...e study appears in the September issue of Alcoholi...s had shown that besides the direct effect of booz...d up and these neuropsychological deficits continu...
Other Medicine News:Health News:Fighting AIDS – a joint venture of the rich and the poor 2Health News:Long term Sobriety can Reverse Effects of Alcohol Damage 2
(Date:5/14/2008)...ate to lead expansion of Cytel,s adaptiv...IDGE, Mass., May 14 /- Cytel Inc., a ... and specialized statistical software,today annou...sident,Adaptive Trials., Judith Quinlan brings o...Cytel team. Prior to joining Cytel Judith spent 10...
(Date:5/14/2008)...stCall/ -- The Quigley,Corporation (Nasdaq: QGLY ...d by its wholly owned subsidiary, Quigley Pharma I...he anti-viral activity of its compound,QR448(a). T...en infected,with Infectious Bronchitis Virus (IBV)...is efficacious against an IBV challenge in two wee...
(Date:5/13/2008)...wire/ -- In women at increased,risk for breast can...routine mammography revealed 28 percent more cance... ultrasound exam substantially increased the,rates...es, according to an,American College of Radiology ... 14, 2008 issue of the Journal of American Medical...
(Date:5/13/2008)...uesday, May 13 at 1:00 p.m. EDT ...ENLO PARK, Calif., May 13 /PRNewswire-FirstCall/,-...itive six-month follow-up,data from the CUSTOM III...icacy of the Custom NX(R) drug eluting stent (DES)...y artery disease., The CUSTOM III clinical trial ...
Breaking Medicine Technology:Judith Quinlan Joins Cytel as Vice President, Adaptive Trials 2Quigley Announces Successful Poultry Study of Chickens With Infectious Bronchitis; Plans to Approach the Poultry Industry for Potential Commercialization 2Quigley Announces Successful Poultry Study of Chickens With Infectious Bronchitis; Plans to Approach the Poultry Industry for Potential Commercialization 3Quigley Announces Successful Poultry Study of Chickens With Infectious Bronchitis; Plans to Approach the Poultry Industry for Potential Commercialization 4Quigley Announces Successful Poultry Study of Chickens With Infectious Bronchitis; Plans to Approach the Poultry Industry for Potential Commercialization 5Adding Breast Ultrasound Screening to Mammography Reveals Cancers not Seen on Mammography Alone in Women at Increased Risk for Breast Cancer 2Adding Breast Ultrasound Screening to Mammography Reveals Cancers not Seen on Mammography Alone in Women at Increased Risk for Breast Cancer 3XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented at EuroPCR Meeting 2XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented at EuroPCR Meeting 3XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented at EuroPCR Meeting 4January American Naturalist highlights 9100 1January American Naturalist highlights 9100 2January American Naturalist highlights 9100 3January American Naturalist highlights 9100 4January American Naturalist highlights 9100 5January American Naturalist highlights 9100 6January American Naturalist highlights 9100 7January American Naturalist highlights 9100 8January American Naturalist highlights 9100 9January American Naturalist highlights 9100 10January American Naturalist highlights 9100 11January American Naturalist highlights 9100 12January American Naturalist highlights 9100 13Surviving childhood cancer the success story 9097 1RxElite Registration Statement Suspended 9094 1RxElite Registration Statement Suspended 9094 2Arizona Patient Protection Act Introduced 9091 1Arizona Patient Protection Act Introduced 9091 2Arizona Patient Protection Act Introduced 9091 3
...rated with signs of durable,disease control in adv..., 2007 /PRNewswire-FirstCall/ -- IDM,Pharma, Inc. ...I,UVIDEM (IDD-3) melanoma vaccine clinical trial (...ll tolerated with evidence of,efficacy and inducti... metastatic melanoma. , The data were presented by...
...sented at ENDO 2007 , ,- Regulatory approvals for ...ruitment in Europe , ,MONTREAL, QUEBEC -- (MARKET ...TH) reported today that 26-week data from,its firs...ipodystrophy were presented today in Toronto at EN...ty. The presentation was made,by Dr. Steve Grinspo...
Other Medicine Technology:IDM Pharma Presents Preliminary Results from Phase II UVIDEM,Melanoma Vaccine Clinical Trial 2IDM Pharma Presents Preliminary Results from Phase II UVIDEM,Melanoma Vaccine Clinical Trial 3IDM Pharma Presents Preliminary Results from Phase II UVIDEM,Melanoma Vaccine Clinical Trial 4IDM Pharma Presents Preliminary Results from Phase II UVIDEM,Melanoma Vaccine Clinical Trial 5Theratechnologies: TH9507 Phase 3 Clinical Update 2Theratechnologies: TH9507 Phase 3 Clinical Update 3
Easy to pierce, remove using foil stripper
Inquire
...eat Sealing Foil and Heat Sealing Film each provid...ts and allow safe and easy sample storage. In auto...asily punctured with standard pipette tips. The He...ng of the sample in the plates. Heat Sealing Foil ...
Inquire
Medicine Products: